Yahoo!   My Yahoo!   Mail  
Search   
Sign In
New User? Sign Up
Home > Investing > RGDX > Summary

Response Genetics, Inc
(RGDX)

1.3199USD   Up0.0399 (3.12%)   
At 1:51AM IST
 Response Genetics, Inc (NCM:RGDX) Delayed quote data 
[Chart]
1d  5d  3m  6m  1y  2y  5y 
Last Trade: 1.3199USD
Trade Time:1:51AM IST
Change:Up0.0399 (3.12%)
Prev Close:1.28
Open:1.26
Bid:1.13 x 500
Ask:N/A
1y Target Est:3.00
Day's Range:1.26 - 1.3199
52wk Range:0.29 - 2.72
Volume:2,700
Avg Vol (3m):8,587.3
Market Cap:20.19M
P/E (ttm):N/A
EPS (ttm):-0.917
Div & Yield:N/A (N/A%)
Add RGDX to Portfolio   Download Data

HEADLINES

 
•RESPONSE GENETICS INC Files SEC form 8-K, Change in Directors or Principal Officers - EDGAR Online  - Wed 3:39AM
•Response Genetics to Present at the 20th Annual UBS Global Healthcare Services Conference and at the 12th Annual BIO CEO & Investor Conference - Business Wire  - Thu, Feb 4
•Response Genetics Announces Appointment of Dr. Edith P. Mitchell to Board of Directors - Business Wire  - Wed, Jan 20
•RESPONSE GENETICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibit - EDGAR Online  - Wed, Jan 20
•Response Genetics to Increase Sales Force by 50 percent to Meet Growing Demand for its ResponseDX Tests - Business Wire  - Mon, Jan 11
•Response Genetics Inc. Announces Distribution Agreement with Genetic Technologies Ltd. to Expand the Availability of ResponseDX Molecular Diagnostic Tests Internationally - Business Wire  - Wed, Jan 6
•RESPONSE GENETICS INC Financials - EDGAR Online Financials  - Fri, Nov 20
•RESPONSE GENETICS INC Files SEC form 10-Q, Quarterly Report - EDGAR Online  - Tue, Nov 17
•Response Genetics, Inc. Reports Third Quarter 2009 Financial Results Driven by 100 Percent Increase in ResponseDX Revenues - Business Wire  - Tue, Nov 17
•Q3 2009 RESPONSE GENETICS INC Earnings Release - After Market Close - CCBN  - Mon, Nov 16
» More Headlines for RGDX...

ANALYST

 
EPS Est (next year) (Dec-09) :N/A
EPS Est (in 2 years) (Dec-10) :N/A
Avg Rec (current)*:3.0
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
» Analyst Opinion» Estimates

BUSINESS SUMMARY

 
Response Genetics, Inc., a life sciences company, engages in the research, development, marketing, and sale of clinical diagnostics and pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and Japan.

» Full Company Profile